Navigation Links
"Cancer Immunotherapy Market & Clinical Pipeline Insight" New Research Study Published by KuicK Research
Date:8/9/2014

Delhi, India (PRWEB) August 09, 2014

Recent years have witnessed the emergence of cancer immunotherapy, which has the potential to offer less toxic and more efficient therapeutic alternatives for patients. Over the past 15 years, the researchers have increased their learning about the human body’s immune system, which has led to the achievement of significant number of regulatory milestones during this period. Cancer immunotherapy has been made commercial and the market availability of the agents has enabled the pharma companies to develop novel combination approaches which have the capability to provide even greater insight into the body’s immune system.

Recently published research study “Cancer Immunotherapy Market & Clinical Pipeline Insight” by KuicK Research study highlights the ongoing developments and trends in the field of cancer immunotherapy. Research study gives comprehensive insight on clinical information like patent analysis, orphan designation, companies developing immunotherapy drugs, on more than 1000 cancer immunotherapy being developed for the treatment of multiple cancers. Report discusses various Antibodies, Cancer Vaccine, Cell Therapies, Oncolytic viruses and cytokines therapies being clinical developed for the treatment of multiple cancers.

“Cancer Immunotherapy Market & Clinical Pipeline Insight” Report Highlights:

  • Cancer Immunotherapy Market Overview
  • Cancer Immunotherapy Market Dynamics
  • Cancer Immunotherapy Pipeline: 1080 Drug in Clinical Pipeline
  • Marketed Cancer Immunotherapy Therapy: 64 Marketed
  • Cancer Monoclonal Antibodies Clinical Pipeline by Phase & Country
  • Cancer Vaccine Clinical Pipeline by Phase & Country
  • Oncolytic Viruses Clinical Pipeline by Phase & Country
  • Cancer Cytokine Therapy Clinical Trial Insight by Phase & Country
  • Cancer Cell Therapy Clinical Trial Insight by Phase & Country
  • Currently there are 605 Cancer Monoclonal Antibodies, 289 Cancer Vaccines, 40 Oncolytic Viruses Drugs, 64 Cytokines Therapies & 82 Cell Therapies in Clinical Pipeline

“Cancer Immunotherapy Market & Clinical Pipeline Insight” report gives insight on the following cancer immunotherapies:

  • Cancer Monoclonal Antibodies: 34 Marketed & 605 In Clinical Development Phases
  • Cancer Vaccines: 12 Marketed & 289 In Clinical Development Phases
  • Cancer Cell Therapy: 3 Marketed & 82 In Clinical Development Phases
  • Cancer Cytokine Therapy: 15 Marketed & 64 In Clinical Development Phases
  • Oncolytic Virus Therapy: 40 In Clinical Development Phases

“Cancer Immunotherapy Market & Clinical Pipeline Insight” report highlights US dominance in the clinical development of cancer immunotherapies followed by European region. Reports discussed the mechanism of immunotherapies, types of immunotherapies, need for cancer immunotherapy, cancer immunotherapy market overview and clinical developments in fields of cancer immunotherapy.

For report sample contact:

Mr. Neeraj Chawla
+91-11-47067990
neeraj(at)kuickresearch(dot)com

Read the full story at http://www.prweb.com/releases/2014/08/prweb12082341.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related biology technology :

1. Leading Cancer Immunotherapy Biotech Startup Announces New Investments, Leadership Appointments
2. Science Magazine: Cancer Immunotherapy is the Medical Breakthrough of 2013; The CBCD Highlights the Link between Immunotherapy and Microcompetition
3. DiaVacss Immunotherapy Product for Treatment of Type 1 Diabetes Receives Orphan Drug Status Designation from the FDA
4. Immunotherapy Offers New Hope for Cancer Patients: One Man’s Alternative Cancer Treatment Journey
5. Leading Cancer Research Centers Team Up To Launch Biotech Startup Focused On Cancer Immunotherapy
6. Argos Therapeutics Presents Data Showing Memory T Cell Expansion After Administration of Fully Personalized Immunotherapy Correlates with Overall Survival Benefit in Patients with Metastatic Renal Cell Carcinoma
7. FDA Review in Journal for ImmunoTherapy of Cancer Offers New Insights into Cancer Immunotherapy Product Development & Clinical Evaluation
8. Advanced Cell Diagnostics Initiates Agreement to Study Biomarkers for Cancer Immunotherapy
9. Tuberculosis Immunotherapy Grant for Immunoxel Honibe Honey Lozenges
10. UroToday Launches New Prostate Cancer Focused Content Including Immunotherapy for Metastatic Castration-resistant Patients
11. Cancer Immunotherapy Expert Joins Pacific Meso Center Research Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 27, 2016 , ... Newly created 4Sight Medical Solutions ... the healthcare market. The company's primary focus is on new product introductions, to ... that are necessary to help companies efficiently bring their products to market. , ...
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
(Date:6/23/2016)... 23, 2016  The Prostate Cancer Foundation (PCF) is pleased to ... faster cures for prostate cancer. Members of the Class of 2016 were selected ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:6/7/2016)... June 7, 2016  Syngrafii Inc. and San ... relationship that includes integrating Syngrafii,s patented LongPen™ eSignature ... This collaboration will result in greater convenience for ... union, while maintaining existing document workflow and compliance ... ...
(Date:6/2/2016)... LONDON , June 2, 2016 ... Systems, Manned Platforms, Unmanned Systems, Physical Infrastructure, Support & ... intelligence provider visiongain offers comprehensive analysis of ... that this market will generate revenues of $17.98 billion ... Systems acquired DVTEL Inc, a leader in software and ...
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
Breaking Biology News(10 mins):